# RC118-ADC

Source: https://onco.cc/drugs/rc118-adc/  
OnCo record `rc118-adc` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

RC118-ADC is an experimental antibody-drug conjugate from RemeGen in phase 2 trials, aimed at Claudin 18.2.

## Summary

RC118-ADC (RC118) is an antibody-drug conjugate developed by RemeGen. Its target is Claudin 18.2 (the sponsor names Claudin 18.2). The sponsor states: An antibody-drug conjugate combining a Claudin 18.2-targeting antibody with a microtubule inhibitor payload. ClinicalTrials.gov describes the intervention as: RC118 for injection is a novel antibody-drug conjugate, with a Claudin 18.2-targeting antibody and a microtube inhibitor. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT05205850, plans to enrol 135 participants with primary completion was scheduled for 2025-09-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Also known as: RC118 for injection
- Tags: pipeline; ctgov-ingest
- Code: RC118
- Modality: ADC
- Mechanism: An antibody-drug conjugate combining a Claudin 18.2-targeting antibody with a microtubule inhibitor payload.

## Sources

- ClinicalTrials.gov: trials of RC118-ADC: https://clinicaltrials.gov/search?intr=RC118

## Connected records

- targets: [Claudin 18.2](https://onco.cc/targets/cldn18-2/)
- companies: [RemeGen](https://onco.cc/companies/remegen/)
- trials: [A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors](https://onco.cc/trials/nct05205850/), [A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors](https://onco.cc/trials/nct06038396/)

---
JSON: https://onco.cc/api/v1/entities/rc118-adc.json